Pfizer Q2 Earnings - Pfizer (NYSE:PFE)

Pfizer Inc PFE has reported a Q2 adjusted EPS of $2.04, up 92% Y/Y, well ahead of the consensus of $1.80.
The company achieved revenues of $27.7 billion, up 53%, beating the Wall Street estimate of $25.98 billion.
Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues.
COVID-19 treatment Paxlovid contributed $8.1 billion in global sales.
The company said it had recorded a $450 million inventory write-off in the second quarter related to its COVID-19 products that had exceeded or are expected to exceed their shelf lives.
FY22 Outlook: Pfizer reaffirms FY22 sales of $98 billion - $102 billion, versus the consensus of $102.92 billion.
The company has revised adjusted EPS guidance to $6.30 - $6.45 versus the earlier guidance of $6.25 - $6.45 and the consensus of $6.62.
Pfizer reiterates COVID-19 vaccine sales of $32 billion and around $22 billion in revenue for Paxlovid.
Price Action: PFE shares are up 1.06% at $52.50 during the premarket session on the last check Thursday.
Photo by x3 from Pixabay

Pfizer Shares Tick Higher On Posting Almost Double Q2 Profits, Reaffirms FY22 Sales Forecast For COVID-19 Products